In a game-changing move, Boston Scientific, Inc. BSX collaborates with Scivita Medical Technology Co., Ltd. to extend their partnership, aiming to broaden the reach of Scivita Medical’s innovative products across various global markets, including China.
For Boston Scientific, this expanded agreement represents a significant opportunity to enhance its Endoscopy business within the MedSurg segment.
The Groundbreaking Scivita Medical
Scivita Medical stands out as a pioneering medical device company specializing in minimally invasive diagnostic and treatment solutions. Focusing on the development and commercialization of medical endoscopes and related products, the company has adopted a ‘Globalization’ strategy. It houses research and development (R&D) centers in China and Japan and has forged strategic alliances with leading entities like Boston Scientific.
Leaning on robust in-house R&D capabilities, Scivita Medical boasts a distinctive technology foundation rooted in five synergistic core technologies. Through this, the company has curated an extensive range of endoscopic and therapeutic products catering to diverse medical procedures conducted by various clinical departments.
Breaking News Insights
The integration of iterative endoscopic technology has revolutionized the endoscopy realm, merging diagnostic and treatment functions. Single-use video scopes have emerged as a key solution to potential cross-infections in conventional endoscopy, positioning themselves as a promising segment for the burgeoning medical endoscope market.
Image Source: Zacks Investment Research
Per a detailed analysis by Frost & Sullivan quoted by Scivita Medical, the global market value of single-use video scopes stood at $0.5 billion in 2020, with projections soaring to $9.2 billion by 2030.
The collaboration between Boston Scientific and Scivita Medical is anticipated to enhance strategic co-development efforts and bolster global distribution initiatives. These initiatives may encompass joint ventures for future endoscopic devices and global distribution avenues for Scivita Medical’s single-use endoscope and imaging gadgets. The Senior Vice President and President of BSX’s Endoscopy division expressed enthusiasm towards advancing ties with Scivita Medical, which will present medical practitioners with an array of device alternatives across different global regions.
Insights into the Industry Landscape
As per a research study, the global endoscopy device market stood at $28.1 billion in 2022 and is projected to witness a 4.6% CAGR by 2032.
Key Highlights of the MedSurg Domain
Boston Scientific continues to witness robust global demand for its expansive range of gastrointestinal and pulmonary treatment options within the Endoscopy business. Notably, the company is making headway in the market with its biliary franchise spearheaded by the AXIOS Stent and Delivery System and the hemostasis, single-use imaging, and metal stents franchises. The fourth quarter of 2023 saw a remarkable 11% organic sales growth in Endoscopy compared to the same quarter in 2022, primarily fueled by significant upticks in AXIOS and single-use scope sales.
Furthermore, in January 2024, BSX sealed a definitive agreement to acquire Axonics, Inc., amplifying its urology portfolio with groundbreaking technologies to tackle urinary and bowel dysfunctions. This addition has paved the way for Boston Scientific’s foray into sacral neuromodulation, a high-growth sector teeming with opportunities to extend care to patients in need.
Moreover, in November 2023, Boston Scientific acquired Relievant Medsystems, Inc., reinforcing its foothold in advanced interventional chronic pain treatments by offering physicians a wide array of evidence-based solutions that target multiple sources of pain, subsequently transforming patients’ lives.
Price Performace Overview
Boston Scientific shares have witnessed a remarkable 29.9% surge in the past six months, outstripping the industry’s 11.3% growth trajectory.
Zacks Rank and Top Picks
Presently, Boston Scientific holds a Zacks Rank #3 (Hold).
Noteworthy stocks in the broader medical domain include Cardinal Health CAH, Stryker SYK, and DaVita DVA. While Cardinal Health and Stryker are both bestowed with a Zacks Rank #2 (Buy), DaVita flaunts a Zacks Rank #1 (Strong Buy) at the moment. To explore today’s Zacks #1 Rank stocks comprehensively, click here.
Cardinal Health’s stock has soared by 50.9% over the past year. Earnings forecasts for Cardinal Health have edged up from $7.28 to $7.29 for fiscal 2024 and from $8.02 to $8.04 for fiscal 2025 over the past 30 days.
Cardinal Health outperformed earnings estimates in each of the last four quarters, delivering an average surprise of 15.6%. In the most recent quarter, it recorded an earnings surprise of 16.67%.
Estimations for Stryker’s 2024 earnings per share have remained steady at $11.86 over the past 30 days. Stryker’s shares surged by 28.5% over the past year compared to the industry’s 5.2% upswing.
Stryker surpassed earnings projections in each of the preceding four quarters, with an average surprise of 5.09%. In its latest reported quarter, it registered an average earnings surprise of 5.81%.
Forecasts for DaVita’s 2024 earnings per share have surged from $8.97 to $9.23 in the last 30 days. DaVita’s shares escalated by 74.4% in the past year against the industry’s 22% rise.
DaVita surpassed earnings predictions in each of the past four quarters, boasting an average surprise of 35.57%. In the most recent quarter, it showcased an average earnings surprise of 22.22%.
The Secret “Sleeper” Stock Unveiled by Zacks
There is a hidden gem in the Artificial Intelligence sector poised for exponential growth. By 2030, the AI industry is forecasted to achieve a monumental economic impact exceeding that of the internet and iPhone combined.
As a gesture of goodwill, Zacks offers a bonus report featuring this transformative stock and 4 other must-have investments. And more.
Download Free ChatGPT Stock Report Right Now >>
Uncover more insights at Zacks Investment Research
The opinions and views expressed here represent those of the author alone and do not necessarily reflect the views of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
